Robert R. Arrigale

** ********** *****

Apt. A

Hartsdale, NY 10530

Home:914-***-**** Email:abocph@r.postjobfree.com

OBJECTIVE: To apply my problem solving skills in cell line development and molecular biology to a challenging research and development position in the pharmaceutical or biotech industry.

SUMMARY: Accomplished molecular biologist with skills capable of delivering and characterizing high titer GMP antibody production cells lines

QUALIFACATIONS: Seventeen years strong biotech/pharma experience with mammalian cell line development and nucleic acid manipulations., Strong communication, problem solving and analytic skills, quick learner.

EXPERIENCE:

PROGENICS PHARMACEUTICALS, INC. Tarrytown, N.Y. 2000-2011

Senior Research Scientist II (2011)

Senior Research Scientist (2006-2011)

Research Scientist (2003-2005)

Associate Research Scientist (2000-2002)

MOLECULAR BIOLOGY

• Isolated total cellular RNA to synthesize cDNAs by RT-PCR for antibody heavy and light chains, viral genes, and mammalian genes

• Created expression constructs of membrane-bound or soluble gene products by PCR or subcloning

• Created functional human-mouse chimeric antibody constructs for anti-cancer, anti-viral, and anti-microbial targets

• Molecular construct analysis by restriction enzyme digestion and subsequent sequence analysis

• Performed bacterial transformations, plasmid purification of various scales to manipulate plasmid constructs of interest

• Designed primers for use in various PCR applications

• Performed Northern and Southern blots to confirm and characterize stable mammalian transfectants

• Provided vector or primer sequences for synthesis and use at CROs

CELL LINE DEVELOPMENT

• For each antibody therapeutic, screened approximately 22,000 wells to obtain best production cell including two rounds of subcloning

• Responsible for generating 8 GMP cells lines with pre-optimization titers of 800-1200 mg/L

• Created GMP stable cell lines utilizing GS (glutathione synthetase) selection in CHO K/SV cells (Lonza Group Ltd. suspension variants)

• Provided the seed vials and documentation for production of a Master Cell Bank of GMP stable cell lines for commercial production

• Responsible for successful sterility and other PTC testing prior to MCB transfer and creation

• Provided technical document listing cell line(s), growth characteristics, initial production titers, related methodology, and reagent documentation to Manufacturing Dept or contract facilities as part of technology transfer

• Assisted with analysis of cell line production and genome stability over 60 generations

• Presented data and findings at various intra- and inter-departmental team or project meetings including Process Development, R&D, and Manufacturing Groups

• Constructed commercial and research-grade stable cell lines in CHO DXB11 utilizing dhfr selection and amplification

• Generated additional research cell lines using various selection methods in HeLa, 3T3 and CHO-S (suspension) cell lines

• Performed stable and/or transient transfections in roller bottles, shaker flasks, and T-flasks for various cell lines, including 3T3, HeLa, COS-7, 293T, and 293FT (suspension)

• Utilized transient transfections to provide research-grade material for protein characterization

PROTEIN CHARACTERIZATIONS

• Verified protein production by immunoprecipitation, SDS-PAGE and western blotting, or ELISA

• Utilized Coumassie or silver staining for PAGE characterization

• Optimized or developed ELISA assays for screening and/or characterization of expressed proteins

• Improved anti-idiotype ELISAs for screening of hybridomas

• Characterized antibody performance in various animal sera using ELISAs

• Analyzed protein expression in cell lines by flow cytometry

• Prepared membrane lysates using non-denaturing conditions for ELISA screening and animal immunizations

OTHER

• Authored SOPs or research protocols as needed

• Assisted with preparation of information and/or technology transfer to contract facilities

• Established and enforced mycoplasma testing procedures for Research and Development department

• Participated in annual trainings for cGMP (refresher and hot topics), radioactivity use and handling, bloodborne pathogens, chemical hygiene and hazardous waste handling.

• Member of voluntary company-wide medical emergency response team (MERT)

• Member of voluntary Medical Emergency Response Team (MERT)

CADUS PHARMACEUTICALS/OSI PHARMACEUTICALS Tarrytown, N.Y. 1998-2000

Associate Research Scientist II

INNOVIR LABS - ALBERT EINSTEIN COLLEGE OF MEDICINE

LIVER RESEARCH CENTER

Bronx, N.Y

1997

Research Technician

AMERICAN HEALTH FOUNDATION - NAYLOR DANA INSTITUTE FOR DISEASE PREVENTION, DEPARTMENT OF PATHOLOGY AND TOXICOLOGY

Valhalla, N.Y.

1991-1995

Senior Research Assistant (1994-95)

Research Assistant (1991-94)

REGENERON PHARMACEUTICALS Tarrytown, N.Y. 1989-1991

Laboratory Assistant

AWARDS:

Progenics Pharmaceuticals, Inc. Employee Recognition Award for Outstanding Contribution June 2008

EDUCATION:

State University of New York (SUNY) at New Paltz

New Paltz, New York

B.S. Biology 1986-1989

SUNY at Westchester Community College

Valhalla, N.Y A.A.S.

Data Processing 1983-1985

PUBLICATIONS:

Marozsan AJ, Ma D, Nagashima KA, Kennedy BJ, Kang YK, Arrigale RR, Donovan GP, Magargal WW, Maddon PJ, Olson WC. Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J Infect Dis. 2012 Sep;206(5):706-13. Epub 2012 Jun 25.

Durso RJ, Andjelic S, Gardner JP, Margitich DJ, Donovan GP, Arrigale RR, Wang X, Maughan MF, Talarico TL, Olmsted RA, Heston WD, Maddon PJ, Olson WC. A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses. Clin Cancer Res. 2007 Jul 1;13(13):3999-4008.

Falkowska E, Durso RJ, Gardner JP, Cormier EG, Arrigale R, Ogawa RN, Donovan GP, Maddon PJ, Olson WC, Dragic T. L-SIGN (CD209L) isoforms differently mediate trans-infection of hepatoma cells by hepatitis C virus pseudoparticles. J Gen Virol. 2006 Sep;87(Pt 9):2571-6.

Schülke N, Varlamova OA, Donovan GP, Ma D, Gardner JP, Morrissey DM, Arrigale RR, Zhan C, Chodera AJ, Surowitz KG, Maddon PJ, Heston WD, Olson WC. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A. 2003 Oct 28; 100(22):12590-5

Gardner JP, Durso RJ, Arrigale RR, Donovan GP, Maddon PJ, Dragic T, Olson WC. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc Natl Acad Sci U S A. 2003 Apr 15; 100(8):4498-503

Contact this candidate